<DOC>
	<DOCNO>NCT00102037</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The purpose clinical research trial understand safe effective Recombinant Activated FVII reduce bleed blood transfusion patient undergo spinal fusion surgery .</brief_summary>
	<brief_title>Use Activated Recombinant FVII Spinal Surgery</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Elective spinal fusion surgery . History thrombotic disorder ( myocardial infarction , deep vein thrombosis , pulmonary embolism , stroke , disseminate intravascular coagulation peripheral artery thrombosis ) Any trauma within last 3 month lead hospitalization &gt; 24 hour Angina know coronary artery disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>